Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Langley

Showing results (301-310 of 345) with videos related to

Pageof 35
Sort By:
Lancet Regional Health. Americas|December 1, 2025
Healthcare costs and resource utilization for acute respiratory syncytial virus pediatric hospitalizations in Canada: a population-based studyNirma Khatri Vadlamudi, Kyle Gomes, Ethan Chow, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 16, 2005
Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteersShelly A McNeil, Scott A Halperin, Joanne M Langley, et al.
Epidemiology and Infection|June 23, 2025
Risk factors for infection with SARS-CoV-2 in a cohort of Canadian healthcare workers: 2020-2023Brenda L Coleman, Nicole M Robertson, Robyn A Harrison, et al.
Vaccine|February 14, 2012
Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of ageScott A Halperin, Brian Ward, Curtis Cooper, et al.
Vaccine|August 12, 2025
Knowledge gaps and research priorities regarding vaccination in pregnancy: A Canadian perspective from the prevention of infections in the maternal-infant dyad (PRIMED) consortiumOlivia F Hunter, Elisabeth McClymont, Oscar Lau, et al.
JAMA|May 2, 2013
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trialSimon R M Dobson, Shelly McNeil, Marc Dionne, et al.
JAMA Network Open|October 4, 2023
Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 PandemicMalou Bourdeau, Nirma Khatri Vadlamudi, Nathalie Bastien, et al.
Human Vaccines & Immunotherapeutics|February 17, 2026
Safety and immunogenicity of an investigational mRNA-lipid nanoparticle-based monovalent influenza vaccine: Results from a phase 1, randomized, dose-escalation studyIsabel Leroux-Roels, Ilse De Coster, Alberto M Borobia, et al.
The New England Journal of Medicine|February 15, 2023
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older AdultsAlberto Papi, Michael G Ison, Joanne M Langley, et al.
Open Forum Infectious Diseases|September 2, 2024
A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12-24 MonthsJoanne M Langley, Terry M Nolan, Mika Rämet, et al.
Pageof 35

Showing results (301-310 of 345) with videos related to

Sort By:
Pageof 35
Lancet Regional Health. Americas|December 1, 2025
Healthcare costs and resource utilization for acute respiratory syncytial virus pediatric hospitalizations in Canada: a population-based studyNirma Khatri Vadlamudi, Kyle Gomes, Ethan Chow, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 16, 2005
Safety and immunogenicity of 26-valent group a streptococcus vaccine in healthy adult volunteersShelly A McNeil, Scott A Halperin, Joanne M Langley, et al.
Epidemiology and Infection|June 23, 2025
Risk factors for infection with SARS-CoV-2 in a cohort of Canadian healthcare workers: 2020-2023Brenda L Coleman, Nicole M Robertson, Robyn A Harrison, et al.
Vaccine|February 14, 2012
Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of ageScott A Halperin, Brian Ward, Curtis Cooper, et al.
Vaccine|August 12, 2025
Knowledge gaps and research priorities regarding vaccination in pregnancy: A Canadian perspective from the prevention of infections in the maternal-infant dyad (PRIMED) consortiumOlivia F Hunter, Elisabeth McClymont, Oscar Lau, et al.
JAMA|May 2, 2013
Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trialSimon R M Dobson, Shelly McNeil, Marc Dionne, et al.
JAMA Network Open|October 4, 2023
Pediatric RSV-Associated Hospitalizations Before and During the COVID-19 PandemicMalou Bourdeau, Nirma Khatri Vadlamudi, Nathalie Bastien, et al.
Human Vaccines & Immunotherapeutics|February 17, 2026
Safety and immunogenicity of an investigational mRNA-lipid nanoparticle-based monovalent influenza vaccine: Results from a phase 1, randomized, dose-escalation studyIsabel Leroux-Roels, Ilse De Coster, Alberto M Borobia, et al.
The New England Journal of Medicine|February 15, 2023
Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older AdultsAlberto Papi, Michael G Ison, Joanne M Langley, et al.
Open Forum Infectious Diseases|September 2, 2024
A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12-24 MonthsJoanne M Langley, Terry M Nolan, Mika Rämet, et al.
Pageof 35